AdjuTec Pharma AS

AdjuTec Pharma Files Three Patents that Strengthens Commercial Potential

Oslo, Norway, 10 May 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company has recently filed three new patent applications enabling their proprietary technology to inhibit an even broader spectrum of bacterial enzymes that cause antibiotics resistance. This will give pipeline products a more attractive position in the market and significantly extend market exclusivity.

Bacteria produce several types of enzymes to combat antibiotics. Adjutec core technology is targeting an enzyme “family” that destroys last-resort antibiotics, increasingly resulting in morbidity and death of patients. As antibiotic resistance spread, each bacteria become clever and produce several types of enzymes. This is challenging to the clinician and requires antibiotics combined with broad-spectrum enzyme inhibitors. The new patents give Adjutec access to such products, which extend patent protection and increase investor and partner attractiveness.

At the world’s largest conference in infection medicine, ECCMID in Copenhagen, Adjutec received significant attention at posters and oral presentations. The latest scientific and market updates strongly supported the need for novel antibiotic products including enzyme inhibitor technologies.

Adjutec is raising capital for the phase 1 program and Bjørn Klem will attend the BioEquity meeting 13-14 May in Dublin. Having completed preclinical development to support the application of starting phase 1, the company wants to increase visibility towards potential R&D and commercial partners. Both Bjørn Klem and Professor Pål Rongved will attend US Bio 5-8 June in Boston this year.
“Securing and expanding market exclusivity of our products is essential for investors. The new patents will strengthen the positioning of our phase 1 ready product APC148 and support other pipeline products. We see great potential for our products in a medical environment that is looking for novel technologies to overcome antibiotic resistance”, comments CEO Bjørn Klem.

About antimicrobial resistance (AMR) –

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit

Please contact:

Follow us on LinkedIn and Twitter